Impact of the Blood Culture Technique on the Diagnosis of Infective Endocarditis
NCT ID: NCT03153384
Last Updated: 2024-03-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
269 participants
OBSERVATIONAL
2017-11-11
2022-07-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Etiology of Endocarditis in Negative Blood Cultures
NCT02816307
Impact of Beta-lactams on the Microbiota and Relative Fecal Abundance of Mulltidrug Resistant Bacteria
NCT03338738
From Commensalism to Pathogenicity: Exploring the Pathophysiology of Bacteremia to Better Understand Enterococcus Faecalis Infective Endocarditis
NCT07313865
Characterization of Enterococcus Faecalis Endocarditis and Impact of Amoxicillin MIC Elevation on Patient Outcome
NCT05530837
Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia
NCT06833593
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
one both experimental and control arm
Each patient experiences two methods of blood cultures.
Blood Culture
For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood Culture
For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Suspected endocarditis: Patients with Duke-Li-ESC 2015 classification as a major morphological criterion or at least two minor criteria, other than a microbiological criterion, will be considered suspicious of infectious endocarditis.
* Not objecting to their inclusion in the study after delivery and explanation of the information form.
* Absence of microbiological documentation sought or available at the time of inclusion (a patient having already had negative blood cultures or being identified during the screening can be included).
Exclusion Criteria
* Any previous antibiotic therapy in the 7 days preceding the inclusion leading to an improvement in the clinical symptomatology.
* State of consciousness not allowing loyal information.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
GOEHRINGER François
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
François Goehringer, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire de Nancy, Nancy, France
Xavier Duval, MD PhD
Role: STUDY_CHAIR
APHP, Hôpital Bichat Claude Bernard, Paris, France.
Christine Selton-Suty, MD
Role: STUDY_CHAIR
Centre Hospitalier Universitaire de Nancy, Nancy, France
Nejla Aissa, MD
Role: STUDY_CHAIR
Centre Hospitalier Universitaire de Nancy, Nancy, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Nord Franche Comté
Belfort, , France
Centre Hospitalier universitaire de Besançon
Besançon, , France
Centre Hospitalier universitaire de Dijon
Dijon, , France
Centre hospitalier Universitaire de Nancy
Nancy, , France
Hopital BIchat Claude Bernard
Paris, , France
Centre Hospitalier Universitaire de Reims
Reims, , France
Centre Hospitalier Univesitaire de Rennes
Rennes, , France
Hôpitaux Civils de Strasbourg
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Arendrup M, Jensen IP, Justesen T. Diagnosing bacteremia at a Danish hospital using one early large blood volume for culture. Scand J Infect Dis. 1996;28(6):609-14. doi: 10.3109/00365549609037969.
Dargere S, Parienti JJ, Roupie E, Gancel PE, Wiel E, Smaiti N, Loiez C, Joly LM, Lemee L, Pestel-Caron M, du Cheyron D, Verdon R, Leclercq R, Cattoir V; UBC study group. Unique blood culture for diagnosis of bloodstream infections in emergency departments: a prospective multicentre study. Clin Microbiol Infect. 2014 Nov;20(11):O920-7. doi: 10.1111/1469-0691.12656. Epub 2014 Jun 14.
The 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015 Nov 21;36(44):3036-7. doi: 10.1093/eurheartj/ehv488.
Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, Bashore T, Corey GR. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000 Apr;30(4):633-8. doi: 10.1086/313753. Epub 2000 Apr 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APJ2015/UNIENDO-GOEHRINGER/SKJ
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.